Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


04.03.2019

4 Ann Oncol
3 Ann Surg Oncol
4 BMC Cancer
3 Br J Cancer
1 Breast Cancer
2 Breast Cancer (Auckl)
3 Breast Cancer Res
7 Breast Cancer Res Treat
4 Breast J
1 Cancer
1 Cancer Lett
1 Carcinogenesis
3 Clin Breast Cancer
3 Clin Cancer Res
2 Eur J Surg Oncol
1 Eur Radiol
1 Int J Oncol
2 J Clin Oncol
1 J Surg Oncol
1 JAMA
1 Lancet
4 Lancet Oncol
1 Nature
1 NPJ Breast Cancer
3 Oncogene
3 Oncol Rep
1 Oncology (Williston Park)
2 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019 Feb 23. pii: 5364015. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. KIM H, Son S
    22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    

  3. SON S, Kim H, Shin I
    23PMatricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    PubMed     Text format    

  4. YAP YS, Ho D, Ng RC, Chan CH, et al
    27PDetection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30.
    PubMed     Text format    


    Ann Surg Oncol

  5. MITTENDORF EA, King TA
    Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Ann Surg Oncol. 2019 Feb 24. pii: 10.1245/s10434-019-07240.
    PubMed     Text format    

  6. WOOD ME, Cuke M, Bedrosian I
    Prevention Therapy for Breast Cancer: How Can We Do Better?
    Ann Surg Oncol. 2019 Feb 23. pii: 10.1245/s10434-019-07243.
    PubMed     Text format    

  7. FLANAGAN MR, Zabor EC, Stempel M, Mangino DA, et al
    Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor.
    Ann Surg Oncol. 2019 Feb 27. pii: 10.1245/s10434-019-07236.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. RUIZ A, Sebagh M, Saffroy R, Allard MA, et al
    Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.
    BMC Cancer. 2019;19:169.
    PubMed     Text format     Abstract available

  9. LIU H, Chang X, Shang H, Li F, et al
    Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review.
    BMC Cancer. 2019;19:172.
    PubMed     Text format     Abstract available

  10. LIU H, Wang SH, Chen SC, Chen CY, et al
    Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
    BMC Cancer. 2019;19:176.
    PubMed     Text format     Abstract available

  11. DE LARA S, Nyqvist J, Werner Ronnerman E, Helou K, et al
    The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    BMC Cancer. 2019;19:187.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. LI N, Kong J, Lin Z, Yang Y, et al
    Ezrin promotes breast cancer progression by modulating AKT signals.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0383.
    PubMed     Text format     Abstract available

  13. MEJDAHL MK, Wohlfahrt J, Holm M, Balslev E, et al
    Breast cancer mortality in synchronous bilateral breast cancer patients.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0403.
    PubMed     Text format     Abstract available

  14. ABDEL-FATAH TMA, Broom RJ, Lu J, Moseley PM, et al
    SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
    Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0405.
    PubMed     Text format     Abstract available


    Breast Cancer

  15. KOTANI H, Ito H, Kuwahara K, Kuzushima K, et al
    Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population.
    Breast Cancer. 2019 Feb 27. pii: 10.1007/s12282-019-00956.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  16. SELLI C, Sims AH
    Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research.
    Breast Cancer (Auckl). 2019;13:1178223419829072.
    PubMed     Text format     Abstract available

  17. MARTINEZ MT, Oltra SS, Pena-Chilet M, Alonso E, et al
    Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator.
    Breast Cancer (Auckl). 2019;13:1178223419828766.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  18. KENSLER KH, Regan MM, Heng YJ, Baker GM, et al
    Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
    Breast Cancer Res. 2019;21:30.
    PubMed     Text format     Abstract available

  19. MORTIMER J, Di Palma J, Schmid K, Ye Y, et al
    Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Breast Cancer Res. 2019;21:32.
    PubMed     Text format     Abstract available

  20. KOLB AD, Shupp AB, Mukhopadhyay D, Marini FC, et al
    Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.
    Breast Cancer Res. 2019;21:31.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  21. AFZALI F, Akbari P, Naderi-Manesh H, Gardaneh M, et al
    The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
    Breast Cancer Res Treat. 2019 Feb 27. pii: 10.1007/s10549-019-05159.
    PubMed     Text format     Abstract available

  22. SAGAWA N, Ohno S, Hiratsuka T, Kondo N, et al
    The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05164.
    PubMed     Text format     Abstract available

  23. WUERSTLEIN R, Kates R, Gluz O, Grischke EM, et al
    Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-018-05075.
    PubMed     Text format     Abstract available

  24. RICE SR, Feigenberg SJ, Hamza M, Molitoris JK, et al
    Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05150.
    PubMed     Text format     Abstract available

  25. ACETO GM, Awadelkarim KD, Di Nicola M, Moscatello C, et al
    Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05168.
    PubMed     Text format     Abstract available

  26. TICE JA, Bissell MCS, Miglioretti DL, Gard CC, et al
    Validation of the breast cancer surveillance consortium model of breast cancer risk.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05167.
    PubMed     Text format     Abstract available

  27. MARKS DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, et al
    The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05169.
    PubMed     Text format     Abstract available


    Breast J

  28. DEFAZIO MV, Graziano FD, Lakhiani C, Pittman TA, et al
    Incidental discovery of partial Poland's sequence during mastectomy for contralateral breast cancer.
    Breast J. 2019 Feb 22. doi: 10.1111/tbj.13210.
    PubMed     Text format    

  29. TONG M, Guo W
    Indocyanine green fluorescence-guided lumpectomy of nonpalpable breast cancer versus wire-guided excision: A randomized clinical trial.
    Breast J. 2019 Feb 22. doi: 10.1111/tbj.13207.
    PubMed     Text format     Abstract available

  30. SWEETING RS, Du L, Shyr Y, Hooks MA, et al
    Income, costs, and health care utilization may influence surgical choice in early stage breast cancer.
    Breast J. 2019 Feb 25. doi: 10.1111/tbj.13223.
    PubMed     Text format    

  31. MARIANI G, Galli G, Cavalieri S, Valagussa P, et al
    Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
    Breast J. 2019 Feb 27. doi: 10.1111/tbj.13197.
    PubMed     Text format     Abstract available


    Cancer

  32. AUMEERUDDY MZ, Mahomoodally MF
    Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32022.
    PubMed     Text format     Abstract available


    Cancer Lett

  33. SOLINAS C, Marcoux D, Garaud S, Vitoria JR, et al
    BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    Cancer Lett. 2019 Feb 21. pii: S0304-3835(19)30105.
    PubMed     Text format     Abstract available


    Carcinogenesis

  34. TANG H, Chen B, Liu P, Xie X, et al
    SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer.
    Carcinogenesis. 2019 Feb 27. pii: 5366034. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  35. HU J, Cuffolo G, Parulekar V, Chan V, et al
    The Results of Surveillance Imaging After Breast Conservation Surgery and Partial Breast Reconstruction With Chest Wall Perforator Flaps; A Qualitative Analysis Compared With Standard Breast-Conserving Surgery for Breast Cancer.
    Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(18)30842.
    PubMed     Text format     Abstract available

  36. FERRIGNI E, Bergom C, Yin Z, Szabo A, et al
    Breast Cancer in Women Aged 80 Years or Older: An Analysis of Treatment Patterns and Disease Outcomes.
    Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(18)30705.
    PubMed     Text format     Abstract available

  37. OGIYA R, Sagara Y, Niikura N, Freedman RA, et al
    Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Clin Breast Cancer. 2019 Jan 29. pii: S1526-8209(18)30604.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  38. DI COSIMO S, Appierto V, Pizzamiglio S, Tiberio P, et al
    Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial.
    Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2507.
    PubMed     Text format     Abstract available

  39. CHUMSRI S, Serie DJ, Li Z, Pogue-Geile KL, et al
    Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2206.
    PubMed     Text format     Abstract available

  40. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
    The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  41. WALSTRA CJEF, Schipper RJ, Poodt IGM, van Riet YE, et al
    Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review.
    Eur J Surg Oncol. 2019 Feb 10. pii: S0748-7983(19)30277.
    PubMed     Text format     Abstract available

  42. NIINIKOSKI L, Leidenius MHK, Vaara P, Voynov A, et al
    Resection margins and local recurrences in breast cancer: Comparison between conventional and oncoplastic breast conserving surgery.
    Eur J Surg Oncol. 2019 Feb 11. pii: S0748-7983(19)30279.
    PubMed     Text format     Abstract available


    Eur Radiol

  43. VREEMANN S, Dalmis MU, Bult P, Karssemeijer N, et al
    Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
    Eur Radiol. 2019 Feb 22. pii: 10.1007/s00330-019-06020.
    PubMed     Text format     Abstract available


    Int J Oncol

  44. SHAO G, Wang M, Fan X, Zhong L, et al
    lncRNA CASC9 positively regulates CHK1 to promote breast cancer cell proliferation and survival through sponging the miR195/497 cluster.
    Int J Oncol. 2019 Feb 28. doi: 10.3892/ijo.2019.4734.
    PubMed     Text format     Abstract available


    J Clin Oncol

  45. REGAN MM, Fleming GF, Walley B, Francis PA, et al
    Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
    J Clin Oncol. 2019 Feb 27:JCO1802433. doi: 10.1200/JCO.18.02433.
    PubMed     Text format    

  46. TURNER NC, Liu Y, Zhu Z, Loi S, et al
    Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2019 Feb 26:JCO1800925. doi: 10.1200/JCO.18.00925.
    PubMed     Text format     Abstract available


    J Surg Oncol

  47. BANKS A, Coronado G, Zimmerman R, Iyengar G, et al
    Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ.
    J Surg Oncol. 2019;119:409-420.
    PubMed     Text format     Abstract available


    JAMA

  48. SLOMSKI A
    BMI Not a Good Proxy for Breast Cancer Risk.
    JAMA. 2019;321:735.
    PubMed     Text format    


    Lancet

  49. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.
    PubMed     Text format    


    Lancet Oncol

  50. GNANT M, Pfeiler G, Steger GG, Egle D, et al
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30862.
    PubMed     Text format     Abstract available

  51. GARCIA-CLOSAS M, Chatterjee N
    Assessment of breast cancer risk: which tools to use?
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(19)30071.
    PubMed     Text format    

  52. TERRY MB, Liao Y, Whittemore AS, Leoce N, et al
    10-year performance of four models of breast cancer risk: a validation study.
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(18)30902.
    PubMed     Text format     Abstract available

  53. LIPPMAN M
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30913.
    PubMed     Text format    


    Nature

  54. ELIA I, Rossi M, Stegen S, Broekaert D, et al
    Breast cancer cells rely on environmental pyruvate to shape the metastatic niche.
    Nature. 2019 Feb 27. pii: 10.1038/s41586-019-0977.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  55. DESMEDT C, Pingitore J, Rothe F, Marchio C, et al
    ESR1 mutations in metastatic lobular breast cancer patients.
    NPJ Breast Cancer. 2019;5:9.
    PubMed     Text format     Abstract available


    Oncogene

  56. HUANG X, Wang XN, Yuan XD, Wu WY, et al
    XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation.
    Oncogene. 2019;38:1448-1460.
    PubMed     Text format     Abstract available

  57. SUN Y, Ding Y, Guo C, Liu C, et al
    alpha-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling.
    Oncogene. 2019 Feb 25. pii: 10.1038/s41388-019-0762.
    PubMed     Text format     Abstract available

  58. CONTRERAS-ZARATE MJ, Day NL, Ormond DR, Borges VF, et al
    Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases.
    Oncogene. 2019 Feb 22. pii: 10.1038/s41388-019-0756.
    PubMed     Text format     Abstract available


    Oncol Rep

  59. DAI X, Geng F, Li M, Liu M, et al
    Tripartite motifcontaining 11 regulates the proliferation and apoptosis of breast cancer cells.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7015.
    PubMed     Text format     Abstract available

  60. JAERAPONG N, Jamil QA, Riha J, Milovanovic D, et al
    Organic aniontransporting polypeptides contribute to the uptake of curcumin and its main metabolites by human breast cancer cells: Impact on antitumor activity.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7011.
    PubMed     Text format     Abstract available

  61. CHEN Y, He Y, Wang X, Lu F, et al
    Adiposederived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells.
    Oncol Rep. 2019 Feb 15. doi: 10.3892/or.2019.7018.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  62. COPELAND AC, Anders CK
    Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.
    Oncology (Williston Park). 2018;32:483-7.
    PubMed     Text format     Abstract available


    PLoS One

  63. XIE L, Sun Z, Hong Z, Brown NJ, et al
    Temporal and molecular dynamics of human metastatic breast carcinoma cell adhesive interactions with human bone marrow endothelium analyzed by single-cell force spectroscopy.
    PLoS One. 2018;13:e0204418.
    PubMed     Text format     Abstract available

  64. JUNG H, Kim B, Lee I, Yoo M, et al
    Detection of masses in mammograms using a one-stage object detector based on a deep convolutional neural network.
    PLoS One. 2018;13:e0203355.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  65. SLEDGE GW
    Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 22. pii: 1900368116.
    PubMed     Text format    

  66. CHUANG PK, Hsiao M, Hsu TL, Chang CF, et al
    Signaling pathway of globo-series glycosphingolipids and beta1,3-galactosyltransferase V (beta3GalT5) in breast cancer.
    Proc Natl Acad Sci U S A. 2019;116:3518-3523.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: